Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707350 | 1.00 | USP30 (0.51) | USP30STSNAMPTACHETACR1 | |
| SCHEMBL10281062 | 1.00 | USP30 (0.51) | USP30STSNAMPTACHETACR1 | |
| SCHEMBL707351 | 1.00 | USP30 (0.51) | USP30STSNAMPTACHETACR1 | |
| SCHEMBL21725293 | 1.00 | USP30 (0.51) | USP30STSNAMPTACHETACR1 | |
| SCHEMBL2253056 | 0.91 | STS (0.53) | USP30STSACHETACR1KEAP1 | |
| SCHEMBL556232 | 0.91 | STS (0.53) | USP30STSACHETACR1KEAP1 | |
| SCHEMBL2252656 | 0.91 | STS (0.53) | USP30STSACHETACR1KEAP1 | |
| SCHEMBL5477496 | 0.90 | GPR119 (0.52) | USP30STSACHETACR1KEAP1 | |
| SCHEMBL556613 | 0.90 | GPR119 (0.52) | USP30STSACHETACR1KEAP1 | |
| SCHEMBL5477485 | 0.90 | GPR119 (0.52) | USP30STSACHETACR1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11349565-A | — | — | None | — | — | JP | disclosed |
| EP-4077305-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867717-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3400228-B1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3400228-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-7834021-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | INCYTE CORPORATION | 2009-10-01 | — | — | US | disclosed |
| WO-2009085584-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | disclosed |
| JP-H11349565-A | PRODUCTION OF PYRIDONECARBOXYLIC ACID DERIVATIVE AND INTERMEDIATE THEREOF | DAINIPPON PHARMACEUT CO LTD | 1999-12-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319809-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKNK2, CYP2J2, PTGS2 | USP30 3328/4885STS 2106/4885NAMPT 861/4885 |
| US-10059718-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | USP30 3328/4885STS 2106/4885NAMPT 861/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | USP30 4471/4885STS 3918/4885NAMPT 4363/4885 |
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | USP30 1285/4885STS 4097/4885NAMPT 2729/4885 |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | NR3C2, MC2R, REN | USP30 4395/4885STS 569/4885NAMPT 2102/4885 |
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | USP30 3328/4885STS 2106/4885NAMPT 861/4885 |
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | MC4R, MC5R, MC2R | USP30 4573/4885STS 4690/4885NAMPT 2052/4885 |
| US-20090247474-A1 | 3-Aminopyrrolidine Derivatives As Modulators Of Chemokine Receptors | CCR2, CXCR3, CCR5 | USP30 4289/4885STS 3948/4885NAMPT 4464/4885 |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | USP30 3728/4885STS 972/4885NAMPT 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.